Literature DB >> 28024944

Impact of sarcopenia on outcome in patients with esophageal resection following neoadjuvant chemotherapy for esophageal cancer.

M Paireder1, R Asari1, I Kristo1, E Rieder1, D Tamandl2, A Ba-Ssalamah2, S F Schoppmann3.   

Abstract

BACKGROUND: Nutritional status and body composition parameters such as sarcopenia are important risk factors for impaired outcome in patients with esophageal cancer. This study was conducted to evaluate the effect of sarcopenia on long-term outcome after esophageal resection following neoadjuvant treatment.
METHODS: Skeletal muscle index (SMI) and body composition parameters were measured in patients receiving neoadjuvant treatment for locally advanced esophageal cancer. Endpoints included relapse-free survival (RFS) and overall survival (OS).
RESULTS: The study included 130 patients. Sarcopenia was found in 80 patients (61.5%). Patients with squamous-cell cancer (SCC) showed a decreased median SMI of 48 (range 28.4-60.8) cm/m2 compared with that of patients with adenocarcinoma (AC) of 52 (range 34.4-74.2) cm/m2, P < 0.001. The presence of sarcopenia had a significant impact on patient outcome: HR 1.69 (1.04-2.75), P = 0.036. Median OS was 20.5 (7.36-33.64) versus 52.1 (13.55-90.65) months in sarcopenic and non-sarcopenic patients, respectively. Sarcopenia was identified as an independent risk factor: HR 1.72 (1.049-2.83), P = 0.032.
CONCLUSION: Our data provide evidence that sarcopenia impacts long-term outcome after esophageal resection in patients who have undergone neoadjuvant therapy. Assessment of the body composition parameter can be a reasonable part of patient selection and may influence treatment methods.
Copyright © 2016 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Body composition parameter; Esophageal cancer; Sarcopenia

Mesh:

Year:  2016        PMID: 28024944     DOI: 10.1016/j.ejso.2016.11.015

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  33 in total

1.  Early oral intake through meticulous chewing after esophagectomy.

Authors:  Ian Wong; Simon Law
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

Review 2.  Chemotherapy-Induced Sarcopenia.

Authors:  Federico Bozzetti
Journal:  Curr Treat Options Oncol       Date:  2020-01-30

3.  Evaluation of the impact of psoas muscle index, a parameter of sarcopenia, in patients with esophageal squamous cell carcinoma receiving neoadjuvant therapy.

Authors:  Yohei Ozawa; Toru Nakano; Yusuke Taniyama; Tadashi Sakurai; Yu Onodera; Kurodo Kamiya; Makoto Hikage; Chiaki Sato; Kai Takaya; Takuro Konno; Michiaki Unno; Takashi Kamei
Journal:  Esophagus       Date:  2019-04-12       Impact factor: 4.230

4.  Association of skeletal muscle loss with the long-term outcomes of esophageal cancer patients treated with neoadjuvant chemotherapy.

Authors:  Naoki Kamitani; Kazuhiro Migita; Sohei Matsumoto; Kohei Wakatsuki; Tomohiro Kunishige; Hiroshi Nakade; Shintaro Miyao; Masayuki Sho
Journal:  Surg Today       Date:  2019-07-15       Impact factor: 2.549

5.  Sarcopenia and Short-Term Outcomes After Esophagectomy: A Meta-analysis.

Authors:  Pei-Yu Wang; Li-Dong Xu; Xian-Kai Chen; Lei Xu; Yong-Kui Yu; Rui-Xiang Zhang; Hai-Bo Sun; Hui-Li Wu; Yin Li
Journal:  Ann Surg Oncol       Date:  2020-02-10       Impact factor: 5.344

6.  Impact of Sarcopenia in Patients with Unresectable Locally Advanced Esophageal Cancer Receiving Chemoradiotherapy.

Authors:  Sho Sato; Chikara Kunisaki; Hideaki Suematsu; Yusaku Tanaka; Hiroshi Miyamoto; Takashi Kosaka; Norio Yukawa; Kuniya Tanaka; Kei Sato; Hirotoshi Akiyama; Itaru Endo
Journal:  In Vivo       Date:  2018 May-Jun       Impact factor: 2.155

7.  Sarcopenia does not affect postoperative complication rates in oesophageal cancer surgery: a systematic review and meta-analysis.

Authors:  D Schizas; M Frountzas; I Lidoriki; E Spartalis; K Toutouzas; D Dimitroulis; T Liakakos; K S Mylonas
Journal:  Ann R Coll Surg Engl       Date:  2019-09-11       Impact factor: 1.891

8.  Sarcopenia during neoadjuvant therapy for oesophageal cancer: characterising the impact on muscle strength and physical performance.

Authors:  Emer M Guinan; S L Doyle; A E Bennett; L O'Neill; J Gannon; J A Elliott; J O'Sullivan; J V Reynolds; J Hussey
Journal:  Support Care Cancer       Date:  2017-12-02       Impact factor: 3.603

Review 9.  Implications of low muscle mass across the continuum of care: a narrative review.

Authors:  Carla M Prado; Sarah A Purcell; Carolyn Alish; Suzette L Pereira; Nicolaas E Deutz; Daren K Heyland; Bret H Goodpaster; Kelly A Tappenden; Steven B Heymsfield
Journal:  Ann Med       Date:  2018-09-12       Impact factor: 4.709

10.  Opportunistic body composition evaluation in patients with esophageal adenocarcinoma: association of survival with 18F-FDG PET/CT muscle metrics.

Authors:  Cathy Zhou; Brent Foster; Rosalie Hagge; Cameron Foster; Leon Lenchik; Abhijit J Chaudhari; Robert D Boutin
Journal:  Ann Nucl Med       Date:  2019-12-10       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.